首页> 外文OA文献 >PCN16 Estimating the Budget Impact of Switching from Bortezomib Intravenous (Iv) to Bortezomib Subcutaneous (Sq) in the Treatment of Relapsed/Refractory Multiple Myeloma (Mm) in Mexico

【2h】

PCN16 Estimating the Budget Impact of Switching from Bortezomib Intravenous (Iv) to Bortezomib Subcutaneous (Sq) in the Treatment of Relapsed/Refractory Multiple Myeloma (Mm) in Mexico

机译：PCN16估计在墨西哥复发/难治性多发性骨髓瘤（Mm）治疗中从硼替佐米静脉（Iv）转换为硼替佐米皮下（Sq）的预算影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Wehler EA; Kowal S; Hernandez-Garduno A; Danese de los Santos L; de Anda JA; Anaya P; Munakata J; Gonzalez L;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. BUDGET IMPACT ANALYSIS OF PANOBINOSTAT - BORTEZOMIB AND DEXAMETHASONE, AS 3RD OR 4TH LINE OF TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN GREECE [J] . Vellopoulou K., Kourlaba G., Delimpasi S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：潘诺司他-硼替佐米和地塞米松治疗希腊复发/耐药性多发性骨髓瘤的3线或4线治疗的预算影响分析
2. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study [J] . Goldschmidt Hartmut, Moreau Philippe, Ludwig Heinz, Leukemia and lymphoma . 2018,第5a6期

机译：Carfilzomib-Dexamethasone与皮下或静脉内硼替佐米复发或难治多骨髓瘤：第3阶段的二级分析致力于研究
3. Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology: RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Lothgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484-491. [J] . Ishak J, Rodrigues F European Journal of Haematology . 2011,第1期

机译：复发/难治性多发性骨髓瘤治疗的成本效益：对方法的反应：RE：Hornberger J，Rickert J，Dhawan R，Liwing J，Aschan J，LothgrenM。硼替佐米在复发/难治性多发性骨髓瘤中的成本效益：瑞典的观点。欧洲血液学杂志，2010年; 85（6）：484-491。
4. TREATMENT OF REFRACTORY ANTIBODY MEDIATED REJECTION WITH BORTEZOMIB IN TWO TRANSPLANT RECIPIENTS: THE IMPACT ON DONOR-SPECIFIC ANTI-HLA ANTIBODIES [C] . John Lunz, Judy Howe, Lawrence Jelinek, Clinical Histocompatibility Workshop. . 2010

机译：治疗难治性抗体在两个移植受者中用硼替佐米介导的抑制剂：对供体特异性抗HLA抗体的影响
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study [O] . Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, 2015

机译：复发性多发性骨髓瘤患者皮下注射或静脉注射硼替佐米：III期MMY-3021研究中的肾功能不全患者亚分析
7. PCN17 A Budget Impact Model Estimating the Financial Impact of Increased Use of Generic Bortezomib Intravenous (Iv) in the Treatment of Relapsed/Refractory Multiple Myeloma (Mm) in Venezuela [O] . Wehler EA, Kowal S, Obando CA, 2015

机译：PCN17一个预算影响模型，用于估计在委内瑞拉治疗中复发性/难治性多发性骨髓瘤（Mm）治疗中增加使用通用硼替佐米静脉（Iv）的财务影响

PCN16 Estimating the Budget Impact of Switching from Bortezomib Intravenous (Iv) to Bortezomib Subcutaneous (Sq) in the Treatment of Relapsed/Refractory Multiple Myeloma (Mm) in Mexico

著录项

引文网络

相似文献

相关主题

期刊订阅